Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JCAR 018

Next Previous
Search
Drug Profile

JCAR 018

Alternative Names: Anti-CD22 chimeric antigen receptor T cell therapy - National Cancer Institute/Opus Bio; Anti-CD22 human single chain variable fragment CAR T cell therapy - National Cancer Institute/Opus Bio; Anti-CD22-CAR T cell therapy - National Cancer Institute/Opus Bio; anti-CD22-CAR transduced T cells - National Cancer Institute/Opus Bio; Anti-CD22-human scFv CAR T cell product - National Cancer Institute/Opus Bio; Anti-CD22-human scFv CAR T cell therapy - National Cancer Institute/Opus Bio

Latest Information Update: 15 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Cancer Institute (USA); Opus Bio
  • Developer National Cancer Institute (USA)
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 07 Dec 2024 Efficacy data from a phase I trial in Acute lymphoblastic leukaemia presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)
  • 29 Oct 2024 National Cancer Institute completes a phase I trial in Acute lymphoblastic leukaemia & Non-Hodgkin's lymphoma (Second-line therapy or greater, In infants, In children, In adolescents, In adults) in USA (IV) (NCT02315612)
  • 13 Nov 2023 National Cancer Institute suspends patient enrolment in a phase I trial in Acute lymphoblastic leukaemia & Non-Hodgkin's lymphoma (Second-line therapy or greater, In infants, In children, In adolescents, In adults) in USA (IV) (NCT02315612)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top